Please join us in welcoming Elizabeth A. Mittendorf, MD, PhD, as a new faculty member in the Department of Surgery.
Elizabeth A. Mittendorf, MD, PhD
Rob and Karen Hale Distinguished Chair in Surgical Oncology, Brigham and Women’s Hospital
Director of Surgical Research, Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) Breast Program
Director, Breast Immuno-Oncology Program, Dana-Farber Cancer Institute
Co-Director, Breast Cancer Clinical Research Program, Breast Oncology Program, Dana-Farber Cancer Institute
Member of the Faculty, Harvard Medical School
Dr. Elizabeth A. Mittendorf is a graduate of Case Western Reserve University School of Medicine in Cleveland, OH where she also completed a residency in General Surgery. After completing her residency, she served on active duty in the United States military before completing a fellowship in Surgical Oncology at the University of Texas MD Anderson Cancer Center in Houston, TX. Dr. Mittendorf also holds a PhD in Immunology from the University of Texas Graduate School of Biomedical Sciences at Houston.
Prior to joining Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Dr. Mittendorf was a professor in the Department of Breast Surgical Oncology at the University of Texas MD Anderson Cancer Center in Houston, TX. She joined the faculty at MD Anderson in 2008.
Dr. Mittendorf is board certified by the America Board of Surgery. She maintains a busy clinical practice and oversees a portfolio of clinical trials as well as a basic laboratory effort.
She is principal investigator on a number of clinical protocols including the phase III PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study, and a multicenter phase II trial investigating the efficacy of a CD8+ T cell eliciting vaccine in combination with trastuzumab which is based on preclinical data generated in her laboratory and follows a phase I trial she conducted demonstrating the combination to be safe. This trial is supported by a Breakthrough Award from the Department of Defense (DoD).
Dr. Mittendorf is also the principal investigator on a multi-center trial supported by the National Cancer Institute (NCI) evaluating the impact of vaccination in patients with ductal carcinoma in situ, a trial evaluating the impact of preoperative radiation therapy on the immune response in breast tumors, as well as two investigator initiated studies evaluating immune checkpoint blockade administered in the presurgical setting to breast cancer patients.
Her laboratory work is focused on identifying novel tumor antigens and investigating aspects of the tumor microenvironment that impact the response to immunotherapy. Specifically, she is investigating mutations in the ESR1 gene as targets for vaccination as well as the impact of standard therapies on the immune microenvironment with the goal of informing rational clinical trials evaluating the addition of immunotherapy to treatment regimens for breast cancer patients. This work is supported by the Komen for the Cure Foundation and the Parker Institute for Cancer Immunotherapy.
